Home > Annual Financials > WANBURY

WANBURY Financial Statement Analysis
[BOM: 524212|NSE : WANBURY]

The Revenues of WANBURY have increased by 3.77% YoY .
The Earnings Per Share (EPS) of WANBURY has decreased by -45.47 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

WANBURY Last 5 Annual Financial Results
[BOM: 524212|NSE : WANBURY]

ConsolidatedMar2025
Mar2024
Mar2023
Mar2022
Mar2021
Revenues ₹600 Cr₹578 Cr₹500 Cr₹511 Cr₹393 Cr
Expenses ₹532 Cr₹506 Cr₹477 Cr₹479 Cr₹377 Cr
Operating Profit (Excl OI) ₹68 Cr₹72 Cr₹23 Cr₹32 Cr₹16 Cr
Other Income ₹12 Cr₹0.90 Cr₹1.01 Cr₹5.09 Cr₹4.75 Cr
Interest ₹37 Cr₹29 Cr₹21 Cr₹21 Cr₹23 Cr
Depreciation ₹13 Cr₹13 Cr₹12 Cr₹11 Cr₹9.75 Cr
Profit Before Tax ₹30 Cr₹56 Cr₹-10 Cr₹81 Cr₹-12 Cr
Profit After Tax ₹31 Cr₹56 Cr₹-10 Cr₹81 Cr₹-13 Cr
Consolidated Net Profit ₹31 Cr₹56 Cr₹-10 Cr₹81 Cr₹-13 Cr
Earnings Per Share (Rs)₹9.32₹17.09₹-3.18₹24.94₹-5.04
PAT Margin (%)5.069.60-2.0415.83-3.20
ROE(%)84.210.000.000.000.00
ROCE(%)35.97101.5629.82428.7887.61
Total Debt/Equity(x)3.375.18-1.86-2.72-1.02

Key Financials

Market Cap : ₹ 897.3 Cr
Revenue (TTM) : ₹ 629.8 Cr
Net Profit(TTM) : ₹ 43.0 Cr
EPS (TTM) : ₹ 12.3
P/E (TTM) : 20.9

Industry Peers & Returns1W1M1Y
WANBURY 9.9% 2.8% 15.1%
SUN PHARMACEUTICAL INDUSTRIES 0.2% 7.1% -7.7%
DIVIS LABORATORIES 1% 16.8% 12.7%
CIPLA -2.7% 3.5% 6.2%
TORRENT PHARMACEUTICALS 0.6% 0.4% 4.7%
DR REDDYS LABORATORIES -6.4% -2.7% -3.9%
MANKIND PHARMA 0.6% -0.6% -0.5%
ZYDUS LIFESCIENCES -1.9% -0.6% 1.2%
LUPIN 0.7% 0.7% -9.2%


WANBURY Revenues
[BOM: 524212|NSE : WANBURY]

Y-o-Y

3.77 %

5 Yr CAGR

11.17 %

Years Revenues % Change
Mar2025 ₹600 Cr
3.77
Mar2024 ₹578 Cr
15.63
Mar2023 ₹500 Cr
-2.26
Mar2022 ₹511 Cr
30.23
Mar2021 ₹393 Cr -


WANBURY Operating Profit
[BOM: 524212|NSE : WANBURY]

Y-o-Y

-6.10 %

5 Yr CAGR

44.17 %

Years Operating Profit % Change
Mar2025 ₹68 Cr
-6.10
Mar2024 ₹72 Cr
212.39
Mar2023 ₹23 Cr
-27.28
Mar2022 ₹32 Cr
102.52
Mar2021 ₹16 Cr -

Operating Margins
Y-o-Y

-9.54 %

5 Yr CAGR

29.70 %

Years Operating Margin% % Change
Mar2025 11.29%
-9.54
Mar2024 12.48%
170.13
Mar2023 4.62%
-25.60
Mar2022 6.21%
55.64
Mar2021 3.99% -

WANBURY Profit After Tax
[BOM: 524212|NSE : WANBURY]

Y-o-Y

-45.44 %

5 Yr CAGR

Positive

Years Profit After Tax % Change
Mar2025 ₹31 Cr
-45.44
Mar2024 ₹56 Cr
Positive
Mar2023 ₹-10 Cr
Negative
Mar2022 ₹81 Cr
Positive
Mar2021 ₹-13 Cr -

PAT Margins
Y-o-Y

-47.29 %

5 Yr CAGR

Positive

Years PAT Margin(%) % Change
Mar2025 5.06 %
-47.29
Mar2024 9.6 %
Positive
Mar2023 -2.04 %
Negative
Mar2022 15.83 %
Positive
Mar2021 -3.2 % -

WANBURY Earnings Per Share (EPS)
[BOM: 524212|NSE : WANBURY]

Y-o-Y

-45.47 %

5 Yr CAGR

Positive

Years EPS % Change
Mar2025 ₹9.32
-45.47
Mar2024 ₹17
Positive
Mar2023 ₹-3.18
Negative
Mar2022 ₹25
Positive
Mar2021 ₹-5.04 -

WANBURY Return on Capital Employed (ROCE)
[BOM: 524212|NSE : WANBURY]

Y-o-Y

-64.58 %

5 Yr CAGR

-19.95 %

Years ROCE % Change
Mar2025 35.97%
-64.58
Mar2024 101.56%
240.58
Mar2023 29.82%
-93.05
Mar2022 428.78%
389.42
Mar2021 87.61% -

WANBURY Share Price vs Sensex

Current Share Price : ₹257.1
Current MarketCap: ₹ 897.3 Cr
Updated EOD on :Oct 30,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
WANBURY

9.9%

2.8%

15.1%

SENSEX

-0.2%

5%

5.4%

WANBURY related INDICES

BSE Indices1W1M1Y
BSE ALLCAP 6.4% 8.9% 7.5%
BSE MIDSMALLCAP 4.7% 9% 8.4%
BSE SMALLCAP 0.9% 3.5% 0.8%
BSE HEALTHCARE -0.8% 4.2% 4.6%
No NSE index found

You may also like the below Video Courses


FAQ about WANBURY Financials


How the annual revenues of WANBURY have changed ?

The Revenues of WANBURY have increased by 3.77% YoY .

How the Earnings per Share (EPS) of WANBURY have changed?

The Earnings Per Share (EPS) of WANBURY has decreased by -45.47 % YoY .